NeoProteomics (Sweden)

NeoProteomics (Sweden) Overview

Founded 2000
Founded
Status Private
Employees 3
Employees
Latest Deal Type Grant
Financing Rounds 2

NeoProteomics (Sweden) General Information

Description

Developer of biomarkers designed to aid sensitive and risk-free cancer diagnosis. The company's biomarkers provide risk-free cancer diagnosis by analyzing platelets role in cancer enabling its users to detect and diagnose various forms of aggressive cancer in which early diagnosis can significantly increase the survival rate of the disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Primary Office
  • C/O Enocson
  • Strandvägen 9
  • 114 56 Stockholm
  • Sweden
+46 070-484 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeoProteomics (Sweden) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NeoProteomics (Sweden)‘s full profile, request access.

Request a free trial

NeoProteomics (Sweden) Executive Team (2)

Name Title Board Seat Contact Info
Johan Enocson Owner & Lead Investor

1 Former Executive

NeoProteomics (Sweden) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NeoProteomics (Sweden)‘s full profile, request access.

Request a free trial